Last reviewed · How we verify

ABT-712 — Competitive Intelligence Brief

ABT-712 (ABT-712) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FGFR1 inhibitor. Area: Oncology.

phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABT-712 (ABT-712) — AbbVie (prior sponsor, Abbott). ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABT-712 TARGET ABT-712 AbbVie (prior sponsor, Abbott) phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1)
AZD0120 AZD0120 AstraZeneca phase 3 FGFR1 inhibitor FGFR1 (Fibroblast Growth Factor Receptor 1)
AZD5335 AZD5335 AstraZeneca phase 3 FGFR1 inhibitor FGFR1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FGFR1 inhibitor class)

  1. AstraZeneca · 2 drugs in this class
  2. AbbVie (prior sponsor, Abbott) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-712 — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-712. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: